- Home
- TRT vs ENLV Comparison
TRT vs ENLV Comparison
Compare TRT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRT | ENLV |
|---|---|---|
| Founded | 1958 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 149.0M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TRT | ENLV |
|---|---|---|
| Price | $11.68 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 858.8K | 431.3K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $32,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $600.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $0.57 |
| 52 Week High | $21.38 | $2.10 |
Technical Indicators
Market Signals| Indicator | TRT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 30.26 |
| Support Level | $9.93 | N/A |
| Resistance Level | $14.78 | $1.23 |
| Average True Range (ATR) | 1.58 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 30.90 | 10.51 |
Price Performance
Historical ComparisonAbout TRT Trio-Tech International
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.